Research ArticleOriginal Articles
Open Access

Celecoxib as an adjuvant to chemotherapy for patients with metastatic colorectal cancer

A randomized controlled clinical study

Tarek M. Mostafa, Mohamed A. Alm El-Din and Amira R. Rashdan
Saudi Medical Journal January 2022, 43 (1) 37-44; DOI: https://doi.org/10.15537/smj.2022.43.1.20210574

References

  1. 1.↵
    1. Siegel RL,
    2. Miller KD,
    3. Goding Sauer A,
    4. Fedewa SA,
    5. Butterly LF,
    6. Anderson JC, et al.
    Colorectal cancer statistics, 2020. CA Cancer J Clin 2020; 70: 145–164.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Woo IS,
    2. Jung YH.
    Metronomic chemotherapy in metastatic colorectal cancer. Cancer Lett 2017; 400: 319–324.
    OpenUrl
  3. 3.↵
    1. Buzzelli JN,
    2. Ouaret D,
    3. Brown G,
    4. Allen PD,
    5. Muschel RJ.
    Colorectal cancer liver metastases organoids retain characteristics of original tumor and acquire chemotherapy resistance. Stem Cell Res 2018; 27: 109–120.
    OpenUrl
  4. 4.↵
    1. Shen Y,
    2. Tong M,
    3. Liang Q,
    4. Guo Y,
    5. Sun HQ,
    6. Zheng W, et al.
    Epigenomics alternations and dynamic transcriptional changes in responses to 5-fluorouracil stimulation reveal mechanisms of acquired drug resistance of colorectal cancer cells. Pharmacogenomics J 2018; 18: 23–28.
    OpenUrl
  5. 5.↵
    1. Pushpakom S,
    2. Iorio F,
    3. Eyers PA,
    4. Escott KJ,
    5. Hopper S,
    6. Wells A, et al.
    Drug repurposing: progress, challenges and recommendations. Nat Rev Drug Discov 2019; 18: 41–58.
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Greten FR,
    2. Grivennikov SI.
    Inflammation and cancer: triggers, mechanisms, and consequences. Immunity 2019; 51: 27–41.
    OpenUrlCrossRefPubMed
  7. 7.↵
    1. Lee JS,
    2. Kim HS,
    3. Hahm KB,
    4. Surh YJ.
    Effects of genetic and pharmacologic inhibition of COX-2 on colitis-associated carcinogenesis in mice. J Cancer Prev 2020; 25: 27–37.
    OpenUrl
  8. 8.↵
    1. Tudor DV,
    2. Bâldea I,
    3. Olteanu DE,
    4. Fischer-Fodor E,
    5. Piroska V,
    6. Lupu M, et al.
    Celecoxib as a valuable adjuvant in cutaneous melanoma treated with trametinib. Int J Mol Sci 2021; 22: 4387.
    OpenUrl
  9. 9.↵
    1. Tołoczko-Iwaniuk N,
    2. Dziemiańczyk-Pakieła D,
    3. Nowaszewska BK,
    4. Celińska-Janowicz K,
    5. Miltyk W.
    Celecoxib in cancer therapy and prevention - review. Curr Drug Targets 2019; 20: 302–315.
    OpenUrl
  10. 10.↵
    1. Chen EY,
    2. Blanke CD,
    3. Haller DG,
    4. Benson AB,
    5. Dragovich T,
    6. Lenz HJ, et al.
    A phase II study of celecoxib with irinotecan, 5-fluorouracil, and leucovorin in patients with previously untreated advanced or metastatic colorectal cancer. Am J Clin Oncol Cancer Clin Trials 2018; 41: 1193–1198.
    OpenUrl
  11. 11.↵
    1. Meyerhardt JA,
    2. Shi Q,
    3. Fuchs CS,
    4. Meyer J,
    5. Niedzwiecki D,
    6. Zemla T, et al.
    Effect of celecoxib vs placebo added to standard adjuvant therapy on disease-free survival among patients with stage III colon cancer: the CALGB/SWOG 80702 (alliance) randomized clinical trial. JAMA 2021; 325: 1277–1286.
    OpenUrl
  12. 12.↵
    1. Eisenhauer EA,
    2. Therasse P,
    3. Bogaerts J,
    4. Schwartz LH,
    5. Sargent D,
    6. Ford R, et al.
    New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228–247.
    OpenUrlCrossRefPubMedWeb of Science
  13. 13.↵
    1. Hammond WA,
    2. Swaika A,
    3. Mody K.
    Pharmacologic resistance in colorectal cancer: a review. Ther Adv Med Oncol 2016; 8: 57–84.
    OpenUrlCrossRef
  14. 14.↵
    1. Yi L,
    2. Zhang W,
    3. Zhang H,
    4. Shen J,
    5. Zou J,
    6. Luo P, et al.
    Systematic review and meta-analysis of the benefit of celecoxib in treating advanced non-small-cell lung cancer. Drug Des Devel Ther 2018; 12: 2455–2466.
    OpenUrl
  15. 15.↵
    1. Guo Q,
    2. Li Q,
    3. Wang J,
    4. Liu M,
    5. Wang Y,
    6. Chen Z, et al.
    A comprehensive evaluation of clinical efficacy and safety of celecoxib in combination with chemotherapy in metastatic or postoperative recurrent gastric cancer patients: a preliminary, three-center, clinical trial study. Medicine (Baltimore) 2019; 98: e16234.
    OpenUrl
  16. 16.
    1. Zhou X,
    2. Wang X,
    3. Zhao Y,
    4. Yi C.
    The role of celecoxib for colorectal cancer treatment: a systematic review. Transl Cancer Res 2018; 7: 1527–1536.
    OpenUrl
  17. 17.↵
    1. Larionova I,
    2. Kazakova E,
    3. Gerashchenko T,
    4. Kzhyshkowska J.
    New angiogenic regulators produced by TAMs: perspective for targeting tumor angiogenesis. Cancers (Basel) 2021; 13: 3253.
    OpenUrl
  18. 18.↵
    1. Saberi-Karimian M,
    2. Katsiki N,
    3. Caraglia M,
    4. Boccellino M,
    5. Majeed M,
    6. Sahebkar A.
    Vascular endothelial growth factor: an important molecular target of curcumin. Crit Rev Food Sci Nutr 2019; 59: 299–312.
    OpenUrl
  19. 19.↵
    1. Xie C,
    2. Xu X,
    3. Wang X,
    4. Wei S,
    5. Shao L,
    6. Chen J, et al.
    Cyclooxygenase-2 induces angiogenesis in pancreatic cancer mediated by prostaglandin E2. Oncol Lett 2018; 16: 940–948.
    OpenUrl
  20. 20.↵
    1. Divella R,
    2. Daniele A,
    3. DE Luca R,
    4. Simone M,
    5. Naglieri E,
    6. Savino E, et al.
    Circulating levels of VEGF and CXCL1 are predictive of metastatic organotropismin in patients with colorectal cancer. Anticancer Res 2017; 37: 4867–4871.
    OpenUrlAbstract/FREE Full Text
  21. 21.↵
    1. Li S,
    2. Jiang M,
    3. Wang L,
    4. Yu S.
    Combined chemotherapy with cyclooxygenase-2 (COX-2) inhibitors in treating human cancers: Recent advancement. Biomed Pharmacother 2020; 129: 110389.
    OpenUrl
  22. 22.↵
    1. Zhao J,
    2. Ou B,
    3. Han D,
    4. Wang P,
    5. Zong Y,
    6. Zhu C, et al.
    Tumor-derived CXCL5 promotes human colorectal cancer metastasis through activation of the ERK/Elk-1/Snail and AKT/GSK3β/β-catenin pathways. Mol Cancer 2017; 16: 70.
    OpenUrlPubMed
  23. 23.↵
    1. Chen C,
    2. Xu ZQ,
    3. Zong YP,
    4. Ou BC,
    5. Shen XH,
    6. Feng H, et al.
    CXCL5 induces tumor angiogenesis via enhancing the expression of FOXD1 mediated by the AKT/NF-κB pathway in colorectal cancer. Cell Death Dis 2019; 10: 178.
    OpenUrlCrossRef
  24. 24.↵
    1. Zuo C,
    2. Hong Y,
    3. Qiu X,
    4. Yang D,
    5. Liu N,
    6. Sheng X, et al.
    Celecoxib suppresses proliferation and metastasis of pancreatic cancer cells by down-regulating STAT3/NF-kB and L1CAM activities. Pancreatology 2018; 18: 328–333.
    OpenUrl
  25. 25.↵
    1. Guégan JP,
    2. Ginestier C,
    3. Charafe-Jauffret E,
    4. Ducret T,
    5. Quignard JF,
    6. Vacher P, et al.
    CD95/Fas and metastatic disease: what does not kill you makes you stronger. Semin Cancer Biol 2020; 60: 121–131.
    OpenUrl
  26. 26.↵
    1. Shantha Kumara H,
    2. Miyagaki H,
    3. Herath SA,
    4. Pettke E,
    5. Yan X,
    6. Cekic V, et al.
    Plasma MMP-2 and MMP-7 levels are elevated first month after surgery and may promote growth of residual metastases. World J Gastrointest Oncol 2021; 13: 879–892.
    OpenUrl
  27. 27.↵
    1. Li Q,
    2. Peng J,
    3. Liu T,
    4. Zhang G.
    Effects of celecoxib on cell apoptosis and Fas, FasL and Bcl-2 expression in a BGC-823 human gastric cancer cell line. Exp Ther Med 2017; 14: 1935–1940.
    OpenUrl
  28. 28.↵
    1. Strizova Z,
    2. Kuchar M,
    3. Capkova L,
    4. Komarc M,
    5. Skrivan J,
    6. Bartunkova J, et al.
    Fas-Fas ligand interplay in the periphery of salivary gland carcinomas as a new checkpoint predictor for disease severity and immunotherapy response. Biomedicines 2021; 9: 402.
    OpenUrl
  29. 29.↵
    1. Peter ME,
    2. Hadji A,
    3. Murmann AE,
    4. Brockway S,
    5. Putzbach W,
    6. Pattanayak A, et al.
    The role of CD95 and CD95 ligand in cancer. Cell Death Differ 2015; 22: 549–559.
    OpenUrlCrossRefPubMed
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools
Bookmark this article

Jump to section

Keywords